The Medical Letter on Drugs and Therapeutics
Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the new aminoglycoside antibiotic plazomicin (Zemdri – Achaogen) for IV treatment of adults with complicated urinary tract infections (cUTIs). Plazomicin is active against multi-drug-resistant Enterobacteriaceae, including strains resistant to other aminoglycosides.

STANDARD TREATMENT OF cUTI — Complicated UTIs (pyuria with a documented pathogen in urine or blood and systemic signs of infection) typically occur in patients with comorbidities such as indwelling urinary catheters. Pyelonephritis is considered a cUTI. Generally, cUTIs are caused by gram-negative bacilli including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa. An oral fluoroquinolone such as ciprofloxacin (Cipro, and generics) or levofloxacin (Levaquin, and generics) is generally used to treat such infections in outpatients, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic
Article code: 1559b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian